CD19/NKG2DL CAR-T Therapeutic
/ Celyad Oncology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 16, 2023
NKG2D-Based Dual CAR T Cells to Overcome Antigen Escape and Improve AntiTumor Efficacy
(IO-SUMMIT EUROPE 2023)
- "In vitro, T cells transduced with these constructs displayed cytotoxic activity, proliferated, and secreted cytokines in presence of WT and CD19 KO B-ALL cancer cells. Since NKG2DL are expressed in many cancer indications and absent from healthy tissues, use of NKG2DL-based dual CAR T cells is an attractive approach to improve anti-tumor efficacy in solid indications."
CAR T-Cell Therapy • Clinical • Hematological Malignancies • Oncology • NKG2D
1 to 1
Of
1
Go to page
1